EyeTherapy Blog News
Athena Vision launches; developing gene therapies for devastating eye diseases
Tue, 24 Nov 2015 11:53:39 +0000
Athena Vision is focused on developing gene therapies for eye diseases based on research conducted at UCL Today sees the launch of Athena Vision Limited a biopharmaceutical company focused on the development of gene therapies to treat a range of devastating eye diseases causing blindness. Launched by UCL Business PLC, the wholly-owned technology transfer company of UCL, […]Read more...
Registration for Retina Day 2015 Now Open!
Wed, 10 Jun 2015 11:37:25 +0000
It’s that time once agin for our annual research day for patients and the public. Retina Day 2015 is a free, one day event is organised by the Gene and Cell Therapy Group, UCL Institute of Ophthalmology and NIHR Moorfields Biomedical Research Centre. Come along to: * Hear about some of the latest innovations in research […]Read more...
UCL RPE65 Gene Therapy Trial Shows Benefit in People with Leber Congenital Amaurosis Type 2 for up to Three Years After Treatment
Tue, 05 May 2015 14:44:39 +0000
We are delighted to be able to announce that yesterday, Monday 4th May, the long-term results of our RPE65 gene therapy trial for Leber Congenital Amaurosis Type 2 (LCA2) were published in the prestigious New England Journal of Medicine. Begun in 2007, this was the world’s first-in-human trial of gene therapy to treat an inherited […]Read more...
Gene and cell therapies for age-related macular degeneration (AMD) and diabetic eye disease
Gene therapy to control the damaging growth of blood vessels
Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. JWB Bainbridge, A Mistry, M De Alwis, E Paleolog, A Baker, AJ Thrasher and RR Ali Gene Ther. 2002; 9 (5): 320-326
EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. KS Balaggan, K Binley, M Esapa, Re MacLaren, S Iqball, Y Duran, RA Pearson, O Kan, SE Barker, AJ Smith, JWB Bainbridge, S Naylor and RR Ali Gene Ther. 2006; 13 (15):1153-1165
Models of disease
Differential modulation of retinal degeneration by Ccl2 and Cx3cr1 chemokine signalling. UF Luhmann, CA Lange, S Robbie, PM Munro, JA Cowing, HE Armer, V Luong, LS Carvalho, RE MacLaren, FW Fitzke, JW Bainbridge and RR Ali PLoS One 2012; 7 (4): e35551
The Drusen-like phenotype in aging Ccl2 knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. UF Luhmann, S Robbie, PM Munro, SE Barker, Y Duran V Luong, FW Fitzke, J Bainbridge, RR Ali & R MacLaren. Invest Ophthalmol Vis Sci. 2009; 50 (12): 5934-43
Von Hippel-Lindau protein in the RPE is essential for the normal ocular growth and vascular development. CAK Lange, UFO Luhmann, FM Moway, EL West, H Sayed, AJ Smith, JC Sodewn, PH Maxwell, RR Ali and JW Bainbridge Development 2012; 139 (13): 2340-50
HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia. FM Mowat, UF Luhmann, AJ Smith, C Lange, Y Duran, S Harten, D Shukla, PH Maxwell, RR Ali and JW Bainbridge. PLoS One 2010; 5 (6): e11103
Clinical disease mechanisms
distribution in advanced poliferative diabetic retinopathy.
CA Lange, P Stavrakas, UF Luhmann, DJ de Silva, RR Ali, ZJ Gregor & JW Bainbridge Am J Ophthalmol. 2011;152 (3): 406-412
Page last modified on 22 oct 12 15:23